Get a head STaRT in the fight against brain tumors

Tough on the tumor. Easier on you and your caregivers.

A radiation treatment specifically designed for use inside the brain, GammaTile Therapy gives patients new hope in the fight against brain tumors. It can eliminate the need for traditional repeat radiation treatments and associated hospital or clinic visits, so patients can focus on what matters most—healing.

Watch this animation, which was designed for patients and caregivers to show how GammaTile Therapy works.

How it works

Your neurosurgeon places GammaTile(s) precisely where and when treatment will help the most—at the tumor site immediately after tumor removal.

Radiation is focused right where it is needed—where the tumor is most likely to recur.

GammaTile is designed to protect healthy tissue, minimizing radiation side effects, including hair loss.[1]

Radiation therapy occurs as you go about your daily life.

The Benefits Are Clear

Improved Local Tumor Control

For patients with recurrent meningiomas and recurrent brain metastases, the use of GammaTile Therapy demonstrated a significant delay in treatment site recurrence compared to their previous treatments.[2,3]

Prevent Radiation Delays

GammaTile®, implanted at the time of surgery, immediately delivers targeted therapeutic radiation to help eradicate residual tumor cells. GammaTile provides consistent and effective radiation ensuring radiation treatment compliance, [5] while preserving healthy tissue and minimizing radiation side effects, including hair loss. [7] With 3 minutes of implant time, there is no more waiting to start radiation.

Get a head STaRT in the fight against brain tumors.

Find a GammaTile Therapy Center near you.

GammaTile Therapy: Clinical Outcomes

Improved local tumor control in patients with recurrent meningiomas and recurrent brain metastases

MENINGIOMA PATIENTS RECURRENCE FREE AT 2 YEARS[6]

BRAIN METASTASES PATIENTS RECURRENCE FREE AT 1 YEAR[3]

Potential to extend overall survival in patients with recurrent glioblastoma (GBM)

RECURRENT GBM PATIENTS MEDIAN OVERALL SURVIVAL[4,6]

Learn about the company that developed GammaTile Therapy.

REFERENCES:

  1. Brachman D, et al. Surgically Targeted Radiation Therapy: Safety Profile of Collagen Tile Brachytherapy in 79 Recurrent, Previously Irradiated Intracranial Neoplasms on a Prospective Clinical Trial. Brachytherapy 18, S35–S36 (2019).
  2. Brachman D, et al. Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas. J Neurosurg 131, 1819–1828 (2019).
  3. Imber B et al. Salvage resec1on plus cesium-131 brachytherapy durably controls post-SRS recurrent brain metastases. J Neuro-oncol 159, 609–618 (2022).
  4. Gessler D, et al. GammaTile® brachytherapy in the treatment of recurrent glioblastomas. Neuro-oncology Adv 4, vdab185 (2021).
  5. Gessler DJ, Ferreira C, Dusenbery K, Chen CC. GammaTile®: surgically targeted radiation therapy for glioblastomas. Future Oncol. 2020;16(30):2445-2455.
  6. Kutuk, T. et al. Surgically targeted radia1on therapy (STaRT) for recurrent brain metastases: Ini1al clinical experience. Brachytherapy (2023) doi:10.1016/j.brachy.2023.08.002.
  7. Nakaji P, Youssef E, Dardis C, Smith K, Pinnaduwage D, Brachman D. Surgically targeted radiation therapy: a prospective trial in 79 recurrent, previously irradiated intracranial neoplasms. Poster presented at: 2019 AANS Annual Scientific Meeting; April 2019; San Diego, CA.